Citations

Clear

17 citation(s) found for "Press, Oliver".

Genomics of aggressive B-cell lymphoma
Rosenthal, Allison , Rimsza, Lisa M. , Rimsza, Lisa, Rosenthal, Allison

Mayo Clinic

Hematology | April 16, 2019 | Volume: 2018 | Issue: 1 | Pages: 69-74

10.1182/asheducation-2018.1.69 | PMID 30504293 Get It

Abstract The growing body of genomic information collected and applied to mature aggressive B-cell lymphoma diagnosis and management has exploded over the last few years due to improved technologies with high-throughput capacity, suitable for use on routine formalin-fixed, paraffin-embedded tissue biopsies, and decreasing costs. These techniques have made evaluation of complete DNA sequences, RNA-expression patterns, translocations, copy-number alterations, loss of heterozygosity, and DNA-methylation patterns possible on a genome-wide level. This chapter will present a case of aggressive B-cell lymphoma and discuss the most important genomic abnormalities that characterize this group of entities in the recent update to the fourth edition of the World Health Organization (WHO) lymphoma classification system. Genomic abnormalities discussed will include those necessary for certain diagnoses such as translocations of MYC, BCL2, or BCL6; gene-expression-profiling categorization; the newly defined Burkitt-like lymphoma with 11q abnormalities; prognostic and predictive mutations, as well as tumor heterogeneity. Finally, our current practices for clinical triage of specimens with a potential diagnosis of aggressive B-cell lymphomas are also described. Options for treatment at relapse, in light of these genomic features, will be discussed in the third presentation from this session.
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Qu, Xiaoyu , Braziel, Rita M., Passerini, Verena , Leonard, John P. , Smith, Sonali M. , Kridel, Robert , Press, Oliver W. , Weigert, Oliver , Friedberg, Jonathan W. , Fang, Min , Press, Oliver , Li, Hongli , Rimsza, Lisa M. , Hsi, Eric D. , Kridel, Robert , LeBlanc, Michael

Mayo Clinic

Blood | November 19, 2018 | Volume: 133 | Issue: 1 | Pages: 81-93

10.1182/blood-2018-07-865428 | PMID 30446494 Get It

Abstract Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P < .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P < .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
Li, Hongli , Leonard, John P. , Kaminski, Mark , Braziel, Rita M., Spier, Catherine, Maloney, David G. , Cheson, Bruce D. , Dakhil, Shaker R. , Smith, Sonali M. , Fisher, Richard I., Friedberg, Jonathan W. , Rimsza, Lisa, Kaminski, Mark S, Spier, Catherine M, Gopal, Ajay K. , Dakhil, Shaker, Press, Oliver W. , Shadman, Mazyar , Rimsza, Lisa M. , LeBlanc, Michael

Mayo Clinic

Journal of Clinical Oncology | January 22, 2018 | Volume: 36 | Issue: 7 | Pages: 697-703

10.1200/jco.2017.74.5083 | PMID 29356608 Get It

Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.
THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
Li, H., Harvey, Yasmin , Chan, Fong Chun , Boyle, M., Straus, David J. , Sweetenham, John , Fanale, Michelle A. , Cook, James R. , Leonard, John P. , Friedberg, Jonathan W. , Gascoyne, Randy D. , Scott, David W. , Mottok, Anja , Evens, Andrew M. , Schöder, Heiko , Bartlett, Nancy L. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S. , LeBlanc, Michael , Steidl, Christian , Rimsza, Lisa M. , Press, Oliver W.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 92-93

10.1002/hon.2437_81 Get It

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Mir, Muhammad A. , Maurer, Matthew J. , Ziesmer, Steven C., Macon, William R. , Link, Brian K. , Syrbu, Sergei , Friedberg, Jonathan W. , Press, Oliver W. , Novak, Anne J. , Ansell, Stephen M. , Slager, Susan L. , Habermann, Thomas M. , Witzig, Thomas E. , LeBlanc, Michael , Cerhan, James R. , Maurer, Matthew , Press, Oliver , Link, Brian K , Syrbu, Sergei

Mayo Clinic

Blood | November 24, 2014 | Volume: 125 | Issue: 6 | Pages: 992-998

10.1182/blood-2014-06-583369 | PMID 25422100 Get It

Key Points Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.
A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era
Hosein, Peter J. , Maragulia, Jocelyn, Salzberg, Matthew, Press, Oliver W. , Bast, Martin, Advani, Ranjana H. , Tibshirani, Robert , Evens, Andrew M. , Islam, Nahida , Leonard, John P. , Martin, Peter , Lossos, Izidore S. , Habermann, Thomas M. , Vose, Julie M. , Zelenetz, Andrew D. , Press, Oliver , Advani, Ranjana H , Evens, Andrew M

Mayo Clinic

British Journal of Haematology | January 27, 2014 | Volume: 165 | Issue: 3 | Pages: 358-363

10.1111/bjh.12753 | PMID 24467658 Get It

SummaryPrimary breast diffuse large B‐cell lymphoma (DLBCL) is a rare subtype of non‐Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow‐up of 4·5 years (range 0·6–20·6 years), the Kaplan–Meier estimated median progression‐free survival was 10·4 years (95% confidence interval [CI] 5·8–14·9 years), and the median overall survival was 14·6 years (95% CI 10·2–19 years). Twelve patients (16%) had CNS relapse. A low stage‐modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage‐modified IPI score is associated with survival.